MedTrace Logo

Denosumab Related Osteonecrossi of the Jaw : : an Emergent and Potentially Complex Bone and Joint Infection

NCT03808285 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2019-02-01

No results posted yet for this study

Summary

The aim of this study is to adescription of mandibular osteomylitis in patients having had a treatment by DENOSUMAB. Indeed, one of the adverse effect ot this molecule is to induce mandibular infection.

Conditions

  • Bone and Joint Infection
  • Osteomyelitis
  • Adverse Drug Event

Interventions

OTHER

mandibular osteomylitis

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • TRISTAN FERRY, MD,PhD · Hospices Civils de Lyon

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03808285 on ClinicalTrials.gov